The individual was identified by travel screening and confirmed diagnosis through fifth day testing, CHCC spokesman Lee Tenorio said.
He said the individual has been safely in quarantine and was moved to the designated isolation area for close monitoring.
In addition, he said CHCC has already initiated contact tracing for the most immediate contacts of the new confirmed case, including passengers on the same flight.
The U.S. Centers for Disease Control and Prevention’s Covid-19 data tracker lists the CNMI as among the U.S. jurisdictions with the lowest number of cases — 0.3 per 100 in the last seven days as of the weekend.
North Dakota ranks the highest with 120.2 per 100 in the last seven days, followed by South Dakota with 116.8 per 100 and Wyoming 114.8 per 100.
Guam ranks No. 48 with 27.2 cases per 100.
The CNMI Covid-19 dashboard shows that only two persons are in isolation and the rest have been released.
Of the 105 cases in the CNMI, 79 were diagnosed through travel screening and 26 were tested through community screening, the latest of which was 102 days ago.
There have been two deaths — the first in March and the second was in April.
Covid-19 Task Force Chairman Warren Villagomez thanked everyone for helping keep the islands safe, but he also urged members of the community to “please continue to adhere to the governor’s directives and follow the three W’s — Wash your hands. Watch your distance. Wear a face covering, and continue with the other proper hygiene practices.”
He also asked community members to be cautious when in large gatherings.
“We will continue to work hard, and thanks also to all the frontliners at all levels most especially the nurses and doctors,” he added.
For her part, CHCC Chief Executive Officer Esther Muna said they are working with the Covid-19 Task Force in planning for the distribution of the vaccine.
The exact date is still unknown, she added, but “it is about making sure that the vaccines are safe and effective.”
She said CHCC has been discussing the vaccine with the CDC and the Food and Drug Administration.
She said the CDC’s Advisory Committee on Immunization Practices is reviewing the data, including clinical trial information, including the different groups’ responses to the vaccine and any side effects experienced.
“As we mentioned before, we are going to be transparent about the safety and efficacy of the vaccine before we start pushing it out to the community,” she added.
